Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization’s database

Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization’s database

Importance: Endocrine therapies (ETs) and inhibitors of cyclin-dependent kinases-4/6 (iCDK4/6s) are a standard treatment in breast cancer. However, data on potential neurocognitive impacts remain inconsistent for ET and are scarce for iCDK4/6s.Objective: To evaluate whether ET and iCDK4/6s are assoc...

Full description

Bibliographic Details
Main Authors: Rachel Prevost, Basile Chretien, Elise-Marie Minoc, Charles Dolladille, Angélique Da-Silva, Ahmad Nehme, Florence Joly, Véronique Lelong-Boulouard, Etienne Bastien
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Pharmacology
Subjects:
breast cancer
endocrine therapy
cyclin-dependent kinase 4/6 inhibitor
neurocognitive impairment
pharmacoepidemiology
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1278682/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1278682/full

Similar Items